CardioComm Solutions Executes Servier Canada Supplier Agreement for Coordination of the Tempo In-Clinic Heart Failure ECG Monitoring Program

Toronto, Ontario--(Newsfile Corp. - November 20, 2017) - Established medical electrocardiogram ("ECG") software and device manufacturer CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company") today confirmed it has entered into a supply and service agreement with Quebec-based Servier Canada Inc. ("Servier") for the coordination of a new handheld ECG monitor loan program.

The three year program entitled "TEMPO" involves the loan of HeartCheck™ ECG monitors to approximately 120 cardiology clinics active in treating heart failure patients across Canada. The specific objective of TEMPO is to facilitate the taking of diagnostic-level, in-office ECG readings at busy practices to help improve the treatment of heart failure patients across the country. The TEMPO program will be supported in compliance with the Innovative Medicines Code of Ethical Practices.

CardioComm was selected as the partner company due to the Company's unique profile as an FDA cleared, ISO certified, CE marked and Health Canada approved company since the Company can provide simple to use and accurate medical software and devices for use in both clinical and consumer markets. CardioComm is the manufacturer of the HeartCheck™ ECG devices and will act as the central point of contact for the participating cardiology clinics throughout the three year program. CardioComm will also be responsible for provisioning the HeartCheck™ devices, responding to all questions related to the HeartCheck™ device and for TEMPO program administration.

CardioComm has been growing its position as a leader in the remote medical diagnostic monitoring industry in supporting hospitals, medical call centers, doctors' offices, patient monitoring and telemedicine platforms. The opportunity to support the pharmaceutical sector is a logical progression for CardioComm, as ECG monitoring is a critical element in clinical studies for the evaluation of new medications, as well as for launch and post-launch of approved medications that have cardio protective effects. CardioComm's technologies hold a unique market advantage for being compliant to HIPAA standards and ECG device agnostic. CardioComm's technology can monitor any number of ECG lead recordings supporting up to 30 days of continuous monitoring and provide a fully auditable end-to-end system for use in patient/physician communication protocols. It also controls computer or cloud-based systems to run any remote monitoring installation.

CardioComm will be providing further updates about their medical and consumer ECG recording technologies and award updates. CardioComm has earned the ISO 13485 certification, is HPB approved, HIPAA compliant and holds clearances for the sale of the HeartCheck™ technologies from the European Union (CE Mark), the USA (FDA), China (CFDA) and Canada (Health Canada). To learn more about the CardioComm's products, please see the Company's websites www.theheartcheck.com and www.cardiocommsolutions.com.

About CardioComm Solutions

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions is headquartered in Toronto, Ontario, Canada.

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x 227
investor.relations@cardiocommsolutions.com
www.cardiocommsolutions.com

About Servier Canada

Servier Canada Inc. is an affiliate of the independent French Servier Group. Its mission is to provide the Canadian medical community and its patients innovative therapeutic solutions. As such, Servier Canada collaborates with various players in the healthcare system including researchers, entrepreneurs and innovators. In addition to these research partners, the Canadian International Center for Therapeutic Research (ICTR) is dedicated to clinical development with more than 50 studies conducted throughout Canada over the last 10 years. More information is available at www.servier.ca.

Forward-looking statements

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.